Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03877289
Other study ID # OxyRCT1
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date October 2008
Est. completion date July 2014

Study information

Verified date December 2022
Source University of Calgary
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary goal of this study is to determine if the addition of the bladder antispasmotic oxybutynin to standard antimicrobial therapy in the treatment of childhood cystitis will decrease the associated pain and discomfort. A randomized, double blind, placebo-controlled clinical trial design will be used. The second goal of this study will be to describe the nature and duration of symptoms associated with uncomplicated cystitis in the paediatric age group. Finally, adverse side effects associated with short term use of oxybutynin will be monitored.


Description:

Roughly half of children age 4 to 16 who are diagnosed with a UTI have cystitis. Adult sufferers of cystitis report terrible scorching with voiding, frequent sensation of the need to void with little results, and aching and pressure in the abdomen and genitals. The management of cystitis in adulthood often includes medication directed at easing pain and discomfort. Little research has been directed at documenting the true incidence of these unpleasant symptoms in paediatric cystitis and virtually no literature exists on the management of the associated pain and discomfort. This study will aim to describe the nature and duration of unpleasant symptoms suffered by children with cystitis and will investigate the efficacy of a possible therapy to ease their suffering. Hypothesis: The investigators feel that oxybutynin is the most suitable agent for the first trial of bladder antispasmodics in paediatric cystitis. The investigators reasoning is as follows: 1. Previous adult studies have favored an anticholinergic agent (flavoxate) over the topical analgesic phenazopyridine in the symptomatic treatment of cystitis. 2. Newer anticholinergic agents such as oxybutynin and tolterodine have been shown to be superior to older anticholinergic agents (such as flavoxate) in the treatment of many uncomfortable conditions of the bladder. 3. Oxybutynin has been extensively studied in children for several non-infectious conditions of the bladder. The safety profile, expected side effects and dosage range have therefore been established for children. 4. Oxybutynin is marketed in a palatable syrup. A placebo can easily be manufactured that is identical in taste, texture, smell, color, and volume. The study will be a randomized, double-blind, placebo controlled clinical trial of oxybutynin therapy for symptom control in paediatric cystitis. Toilet trained children aged 4 - 16 years who present to the Alberta Children's Hospital (ACH) emergency room and receive a diagnosis of cystitis are eligible to participate.


Recruitment information / eligibility

Status Completed
Enrollment 81
Est. completion date July 2014
Est. primary completion date July 2014
Accepts healthy volunteers No
Gender All
Age group 4 Years to 16 Years
Eligibility Inclusion Criteria: 1. Age 4 - 16 years 2. Suspected diagnosis of cystitis based on a clean catch or catheter urinalysis (must have at least one of the three screening tests positive - leukocyte esterase, nitrites, or leukocytosis or bactiuria on microscopy) 3. Intention to manage patient as an out-patient with oral antibiotics 4. Parent must be available to assist younger children with the measurements for 24 hours and must be willing to receive follow-up calls daily until symptoms resolve 5. Written informed consent (and assent when age-appropriate) Exclusion Criteria: 1. Clinically suspected pyelonephritis (ED temperature > 38.5, significant flank pain, vomiting > 3 times/24 hours) 2. Patient not toilet trained 3. Patient with significant language delays (preventing use of the facial pain scale) 4. Patient with sensory deficits at the sacral level 5. Inability of the patient and parent to speak and understand English 6. Known contraindication to Oxybutynin (hypersensitivity, glaucoma, bowel obstruction, megacolon, ulcerative colitis, myesthenia gravis, renal or hepatic disease, hyperthyroidism, heart disease, and obstructive uropathy) 7. Patient on any medications during the preceding 8 hours that have analgesic or anticholinergic properties (acetominophen, and inhaled medications will be permitted) 8. Patients who have been previously enrolled in the study 9. Lack of a telephone in the home 10. Known or suspected pregnancy or lactation in the patient 11. Treating physician uses pyridium

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Oxybutynin
Oxybutynin is a tertiary amine anticholinergic. It exerts both antispasmodic and antimuscarinic activity on smooth muscle. It also exerts analgesic and local anaesthetic effects.
Other:
"Orasweet" Liquid Placebo
A formulated Oxybutynin placebo that is nearly identical in appearance, volume, weight, taste, and smell.
Drug:
Antibiotics
All patients in treatment and control arms were treated as a co-intervention with an oral antibioitic, the type of which was chosen by the child's attending physician. Possible prescribed antibiotics include: trimethoprim and sulfamethoxazole (Septra), Cefalotin, Cephalexin, Cefapirin, Cefdroxil, Cefazolin, Cefradine, Cefacetrile, Cefaloridine, Cefroxadine, Cefatrizine, Cefuroxime, Cefixime, amoxicillin/clavulanic acid (Clavulin), and Nitrofurantoin.

Locations

Country Name City State
Canada Alberta Children's Hospital Calgary Alberta

Sponsors (1)

Lead Sponsor Collaborator
University of Calgary

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain/discomfort ratings obtained at 4 hours after each of the three doses of study medication. Participants will be asked to rate how they feel at each of these times using the McGrath Facial Affective Scale (MFAS). The MFAS ranges from the lowest pain score A (happy face) to the highest pain score I (very unhappy crying face). Data will be acquired over a 4 hours after the oxybutynin is given, therefore the investigators can expect that some of the measurements will be disrupted by nighttime sleep for some of the participants. Parents will be asked to document if their child is sleeping during the time when measurements are to be made. Four hours after each of the three doses of study medication.
Secondary Measurements of pain/discomfort with each urination recorded during the first 24 hours. Measurements will be made using the McGrath Facial Affective Scale and will be recorded by the participant or family member at home. Immediate 24 hours after presenting to the ED.
Secondary Number of supplemental doses of acetominophen used during the first 24 hours of the study. This information will be recorded by the participant or caregiver at home. Immediate 24 hours after presenting to the ED.
See also
  Status Clinical Trial Phase
Withdrawn NCT00361998 - Nitrofurantoin Macrocrystals 3 Days Versus 7 Days in the Treatment of Women With Uncomplicated Cystitis Phase 4
Completed NCT03275623 - Management of Sub-Clinical Bacteriuria in Pregnancy Phase 4
Not yet recruiting NCT05055544 - Bearberry in the Treatment of Cystitis N/A
Active, not recruiting NCT01966653 - Study Comparing Nitrofurantoin to Fosfomycin for Acute Urinary Tract Infection in Women Phase 4
Withdrawn NCT01527019 - Comparison in the Treatment of Acute Cystitis Using Cephalosporin and Norfloxacin (CECI) Phase 3
Completed NCT05584657 - Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women Phase 3
Terminated NCT00164099 - The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study Phase 4
Completed NCT00528476 - Risk Factors for Recurrent Urinary Tract Infection in Children N/A
Completed NCT04987164 - Incidence of Cystitis in Women Consuming a Mixture of Cranberry, Cinnamon, Probiotics
Completed NCT01861353 - Cranberry-lingonberry Juice Started During Acute Infection in Prevention of Urinary Tract Infections in Children N/A
Completed NCT00957333 - Effects of Ketamine on Human Bladders and Its Possible Mechanisms N/A
Completed NCT05945667 - Efficacy and Safety of Uronext® in Women With Cystitis N/A
Recruiting NCT05360914 - Hospital at Home for Elderly Acute Ill Patients N/A
Completed NCT04272281 - Use of a Share Decision Making Tool in the Care of Acute Cystitis Without Risk of Complication in Primary Care N/A
Completed NCT03425396 - Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis Phase 2
Completed NCT05260554 - Effect of Cranberry Extract on the Urinary System
Unknown status NCT00622076 - Postoperative Catheterization After Anterior Colporrhaphy N/A
Completed NCT00801021 - Treatment and/or Prevention of Urinary Tract Infections Phase 1
Terminated NCT01060254 - A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain Phase 2
Not yet recruiting NCT06391164 - Study to Evaluate the Efficacy and Safety of XC243 in Patients With Exacerbation of Chronic Cystitis Phase 2